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Trypanosomiasis is one of the major parasitic diseases for which control is still far from reality. The vaccination approaches by
using dominant surface proteins have not been successful, mainly due to antigenic variation of the parasite surface coat. On the
other hand, the chemotherapeutic drugs in current use for the treatment of this disease are toxic and problems of resistance are
increasing (see Kennedy (2004) and Legros et al. (2002)). Therefore, alternative approaches in both treatment and vaccination
against trypanosomiasis are needed at this time. To be able to design and develop such alternatives, the biology of this parasite
and the host response against the pathogen need to be studied. These two aspects of this disease with few examples of alternative
approaches are discussed here.
1.Introduction
Trypanosomiasis is a fatal disease of both human and
livestock. Besides death, it causes a heavy economic loss
mainly in Africa. The etiological agent of the disease is
a unicellular ﬂagellated protozoan parasite of the genus
Trypanosoma. Trypanosomes (20–30μm × 1.5–3.5μm) are
blood-borne unicellular protozoan parasites dwelling in
various body and tissue ﬂuids. These parasites are motile due
to the undulatory motion of their ﬂagellum. The parasite
is known for more than a century, but still the control of
the disease remains elusive. Trypanosomes are the causative
agent of human African trypanosomiasis (HAT), also known
as “sleeping sickness”. The term “sleeping sickness” describes
the deregulation of the sleep-wake cycle and the intrasleep
cycle which is observed in the late stage of the disease [1].
Sleeping sickness is caused by Trypanosoma brucei rhode-
siense in Eastern and Southern Africa and by Trypanosoma
brucei gambiense in Western and Central Africa. Both proto-
zoan species are morphologically indistinguishable, but have
drastically diﬀerent epidemiological features. Both forms of
the sleeping sickness aﬀect the central nervous system. The
typical East African form of trypanosomiasis is characterized
by a rapid and acute development of the disease, and
untreated patients can die within weeks or months of the
infection, whereas the West African form of this disease is
more chronic that can last for several years. According to
WHO reports, African sleeping sickness is the third most
important contributor to the global burden of the parasitic
diseases after malaria and schistosomiasis, if the Disability
Adjusted Life Year (DALY) ﬁgures (i.e., loss of healthy life
years by premature mortality and disability) are considered
[2]. More than 60 million people are at risk of infection
withhumanAfricantrypanosomiasis,withabout45,000new
cases reported annually. It is estimated that at least 300,000–
500,000 people are presently infected. However, less than
4 million people are under surveillance and as such, it is
estimated that less than 10% of the new cases are diagnosed
and treated [3].
Several species of hematophagous glossina, commonly
known as tsetse ﬂies (Glossina spp.) are the vectors of
the African trypanosomes and are responsible for cyclical
transmission of the parasitic protozoan between numerous
vertebrate hosts. The vector is distributed over a wide range
of habitats covering about 10 million square kilometer
potential grazing lands in 37 countries which are rendered
unsuitable for livestock breeding and farming in Africa [4].
Trypanosome infections in livestock are known as
Nagana and Surra. Animal trypanosomiasis, caused by a
wider number of trypanosome species and carried with2 Journal of Biomedicine and Biotechnology
higher prevalence by a greater number of glossina species, is
invariably the greater epidemic across the African continent
withdirecteconomicconsequences.Ingeneral,trypanosome
infections that threaten livestock have a 100 to 150-fold
higher prevalence than the HAT [5]. Historically, the impact
of animal trypanosomiasis has been so profound, that it
has inﬂuenced the migration routes of cattle-owning tribes
that were forced to avoid the G. morsitans “ﬂy-belts” [6]
(Figure 1), as well as the movements of early European and
Arab settlers whodepended on horses and oxen in Africa [7].
Although trypanosomiasis is often referred to as African
trypanosomiasis, certain trypanosomes do cause infections
outside this continent. T. evansi, the causative agent of
“surra” occurs not only in Africa, but also in Central and
South America, the Middle East, and Asia. It causes a
disease in camels, horses, cattle, pigs, buﬀaloes, and dogs. In
Southeast Asia, T. evansi infection is a disease of economic
importance since it aﬀects the health of buﬀalo, cattle,
and swine [8]. The acute stage symptoms of this disease
include abortion, central nervous system disorders, and even
death, while in the chronic condition; working capacity and
productivity of the animals are aﬀe c t e d .E v e nt h o u g hi ti s
generally considered as a livestock disease, there are now
recent reports of the human T. evansi trypanosomiasis in
India [9, 10].
2. GeneralFeatures of Trypanosomes
2.1. Classiﬁcation of Trypanosome. The protozoal parasite
trypanosomes are grouped in the order “kinetoplastida”
because of the presence of a kinetoplast (discussed later).
Based on the mode of transmission by their insect vector,
the genus Trypanosoma is divided in two main groups: ster-
coraria and salivaria [11, 12]( Figure 2). The development
of stercoraria parasites takes place in the intestinal track of
the invertebrate vector and the infection to the vertebrate
is via feces. T. cruzi, the causative agent of Chagas’ disease,
is an example of the stercoraria group. On the other hand,
salivarianparasitescolonizethestomachoftheirinvertebrate
vector, but never pass to the intestinal track. Rather, they
migrate towards the salivary gland of the vector where the
infectious form for vertebrate host develops. Infection of the
vertebrate occurs via saliva when the vector bites in order
to take the blood meal. The African parasites, T. brucei, T.
congolense, T. evansi, and T. equiperdum all belong to the
salavarian group. T. brucei has three subgenera; while T. b.
brucei is the causative agent of Nagana, a cattle disease in
Africa, T. b. rhodesiense and T. b. gambiense are the causative
agents of the sleeping sickness in human. The other two
species T. congolense and T. vivax are the major causative
agents of animal trypanosomiasis in Africa. T. equiperdum is
thecausativeagentof anequinevenerealdiseasethatiscalled
“dourine” where the parasites are transmitted during coitus.
T. evansi causes a livestock disease called “surra”.
2.2. Life Cycle. Trypanosomes are the excellent examples
of organisms that display an extreme adaptation to their
environment, in many cases because they must evade
the immune response of the host. African trypanosomes
are transmitted between mammalian hosts by tsetse ﬂies.
However, in each host, the parasites undergo many life cycle
stages involving forms with discrete morphologies, patterns
of gene expression, and proliferation status. In each case,
thesedevelopmentalchangesareprogrammedprecisely[13].
Infection in the mammalian host begins when the infective
stage,knownasthemetacyclicstage,isinjectedintradermally
by the tsetse ﬂy (Figure 3). The organisms rapidly transform
into the blood-stage trypomastigotes (long, slender forms),
and divide by binary ﬁssion in the interstitial spaces at
the site of the bite. The buildup of metabolic wastes
and cell debris leads to the formation of a “chancre”.
In the mammalian host, the metacyclic parasites rapidly
undergo cell cycle reentry and morphological changes, and
exchange the restricted repertoire for antigenic variation
that is the characteristics of the metacyclic forms with a
more elaborate system of the bloodstream forms [14]. Once
established in the mammalian host, the bloodstream parasite
isheterogeneous[15,16]comprisingtheproliferativeslender
forms during the ascending phase of parasitemia and the
nonproliferative stumpy forms at the peak of parasitemia
[17]. The transition from the morphological extremes (i.e.,
theslenderversusstumpyforms)involvesaprogressionfrom
proliferation to cell cycle arrest, accompanied by a series of
biologicalandmorphologicaltransformations[18,19].Once
stumpy forms develop during the course of parasitemia,
the population is preadapted for transition to the procyclic
forms, which occupy and proliferate in the midgut of the
tsetse. The key features of the stumpy formation are the
cell cycle arrest, the elaboration of some mitochondrial
activities, and a relative resistance to lysis by antibodies
[20, 21] or to the proteolytic environment that might be
encountered in the midgut of tsetse [21, 22]. When the
vector-ﬂy (tsetse) bites to an infected individual, it takes
the parasites with the blood meal. The parasites undergo
metabolic changes in the midgut of the ﬂy. They lose their
surface coat, which consists of about 107 molecules of the
Variant Speciﬁc Surface Glycoprotein (VSG), and transform
into the proliferative procyclic forms. In this form, they
express their own surface proteins called the Procyclic Acidic
Repetitive Proteins (PARPs, or procyclins). The deﬁning
events of the diﬀerentiation from the bloodstream forms
to the procyclic forms are the loss of VSG and gain of the
procyclins. VSG loss occurs very rapidly and involves the
combined action of glycosyl-phosphatidyl-inositol-speciﬁc
phospholipase C (GPI-PLC) and a proteolytic cleavage of the
VSG via a zinc metalloprotease [23–26]. The transformation
to procyclic form also changes the energy generation from
being exclusively based on glycolysis in the bloodstream to
a mitochondrion-based respiratory system, which requires
a structural elaboration and the metabolic activation of
organelle [27]. For successful transmission, the parasite
u n d e r g o e st w os t a g e so fd i ﬀerentiation in the ﬂy: ﬁrst,
establishment in the midgut and then maturation in the
mouthparts or the salivary gland. It is generally thought
that during normal development in the ﬂy, there are no
intracellularstagesandtheparasitesdonotcrossanepithelial
barrier to enter the ﬂy. After proliferation in the tsetseJournal of Biomedicine and Biotechnology 3
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Figure 1: Distribution of tsetse and cattle raising area in Africa http://pathmicro.med.sc.edu/lecture/trypanosomiasis.htm.
midgut, the parasite migrates to the salivary gland. The
epimastigote forms generated there attach to the gland
through elaboration of the ﬂagellar membrane. After further
multiplication, the parasite undergoes division arrest, re-
acquires a VSG coat, and is released into the salivary
gland lumen, in preparation for an inoculation into a new
mammalian host [27].
If the tsetse ﬂies ingest more than one strain of
trypanosome, there is the possibility of genetic exchange
between the two strains, generating an increase in the genetic
diversity in an organism that may not have a true sexual
cycle. Indeed, it was shown by laboratory crosses that genetic
exchange in the African trypanosome is possible [28–33].
Precisely at which stage of the life cycle this genetic exchange
takes place is equivocal, suggesting at the midgut stage [34],
in the salivary gland of the ﬂy [35], and possibly at the
proventriculus and foregut stage [36]. Though there are
conﬂicting results for the stage at which this exchange takes
place, it is shown that this is not a compulsory process. The
mechanism of genetic exchange in T. brucei is still unclear
though it appears to be a true sexual process involving
meiosis [35]. However, no haploid stage has been observed
and the intermediates in the process are still a matter
of conjecture. The frequency of sex in trypanosomes in
nature is also a matter for speculation and controversy, with
conﬂicting results arising from population genetics [37, 38].
In contrast to tsetse transmitted trypanosomes, T. evansi
is transmitted mechanically by the blood sucking insects,
in Asia especially by the horseﬂies (Tabanus spp.) and the
stable ﬂies (Stomoxys spp.), and in Africa the tsetse ﬂy, like
other biting ﬂies, can act as mechanical vector. In South
and Central America, in addition to blood sucking ﬂies, T.
evansicanalsobetransmittedbythevampirebats(Dosmodus
rotundus). Besides mechanical transmission by insects and4 Journal of Biomedicine and Biotechnology
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Figure 2: Classiﬁcation of trypanosomes.
vampire bats, T. evansi can be transmitted through milk or
during coitus [39]. Developmental stages were not observed
in any of the vectors mentioned above. A procyclic or insect
stage does not exist in T. evansi which is attributed to the lack
of maxi circles in the kinetoplast DNA (discussed later) [40].
3.SpecialFeaturesof Trypanosomes
Kinetoplasts are eukaryotes and hence exhibit conventional
features such as the presence of a nucleus delimited by a
nuclear membrane and organelles such as the endoplas-
mic reticulum, the Golgi apparatus, the endo/exocytosis
system, the mitochondrion, and so forth [41]. However,
many of these organelles exhibit speciﬁc and sometimes
extreme features often found only in the kinetoplastids. As
trypanosomes have a dual host life cycle, they have some
speciﬁc adaptation characteristics at diﬀerent levels, that is,
DNA,RNA,andcellularorganization.Thisincludesthepres-
ence of a kinetoplast DNA, ﬂagellum and ﬂagellar pocket,
unique gene regulation, RNA-editing, and the presence of
glycosomes.
3.1.KinetoplastDNA. Beingaeukaryote,trypanosomescon-
tain mitochondria, however, there is only a single mitochon-
drion per cell, which is extremely large and elongated, and
its whole DNA content is condensed in a substructure called
the kinetoplast [42]. The mitochondrial DNA makes up 10–
20%ofthetotalcellularDNAwithanunusualnetworkinthe
kinetoplast which is called kinetoplast DNA (kDNA) [43].
ThekDNAisaplanernetworkcomposedofseveralthousand
topologically interlocked DNA circles. The network contains
two types of circles of diﬀerent sizes: minicircles of about
1kb and maxicircles of 22kb [44, 45]. Maxicircles number
in dozen per cell with conserved sequences and code for
ribosomal RNA and some mitochondrial proteins [46].
Many of the maxicircle transcripts are cryptic and require
editing to form a functional mRNA. Editing speciﬁcity is
controlled by the minicircle-encoded guide RNA (gRNA)
that serve as a template [47]. The minicircles are in high
copy number (5000–10000 per cell) and their sequences vary
between each other [48]. No transfer RNA (tRNA) genes
are found neither in the maxi-circle nor the minicircles
[49, 50]. So all the tRNAs necessary for protein translation of
mitochondrial origin may be nuclear-encoded and imported
from the cytosol into the mitochondrion [49, 51]. Unlike
other trypanosomes, the kDNA of T. evansi does not contain
maxicircle [40].
3.2. The Flagellum and Flagellar Pocket. Trypanosomatids
possess a single ﬂagellum that exits from a ﬂagellar pocket,
a specialized invagination of the plasma membrane where
the entirety of endocytosis/exocytosis traﬃc takes place. In
Trypanosoma spp., the ﬂagellum is attached along the cell
body for most of its length, with the exception of the distal
tip [42]. The site of attachment deﬁnes a specialized region
of the ﬂagellum and of the cell body called the ﬂagellum
attachment zone (FAZ). The ﬂagellum could accomplish
several functions. Firstly, it is involved in the cell motility;
trypanosomes are actively motile cells, swimming at average
speeds of 10–30μm per second in the culture medium [52].
The ﬂagellar motility is required for the viability of the
bloodstream trypanosomes [53]. A striking feature is the fact
that trypanosomes swim with their ﬂagellum leading, that is,
the ﬂagellum drags the cell behind it. This is related to the
way wave forms are initiated: from tip to base, and not from
base to tip as seen in the majority of ﬂagellated organisms
[42]. Secondly, the ﬂagellum is involved in the attachment
of the parasite to the host surfaces. Thirdly, the ﬂagellum
plays a role in the morphogenesis and the cell division
[54, 55]. The ﬂagellar pocket is a ﬂask-shaped invagination
of the plasma membrane where the ﬂagellum emerges out
from the plasma membrane [56]. This pocket constitutes
a highly diﬀerentiated region that facilitates internalization
of host macromolecules, while restricting host access to
the exposed, endocytic receptors of the parasites [57]. The
contribution of the ﬂagellar pocket to protein traﬃcking,
immune evasion, and other processes has been recently
reviewed [58].Journal of Biomedicine and Biotechnology 5
3.3. RNA Editing. Most trypanosomatid mitochondrial
mRNAsundergoRNAeditingbywhichtheprecursormRNA
(pre-mRNA) sequences are changed, often extensively, by
the insertion and less frequently the deletion of uridine
nucleotides (Us) [59]. The pre-mRNAs are encoded in the
maxicircles, whereas the minicircles encode gRNA that spec-
ifytheediting.TheeditinginT. brucei iscatalyzedbycompo-
sitionally and functionally distinct multiprotein complexes,
called editosomes [60]. In this editing process up to half of
the nucleotides can be added. This is a posttranscriptional
process responsible for correcting the coding sequences of
the mRNAs. Recently it had been shown that the structural
conformation of gRNA and the thermodynamic stability of
the gRNA-mRNA binary complex are very important for the
editing to proceed [61]. It has been shown by comparing the
rRNA synthesis in the bloodstream and the insect life-stages
that the mitochondrial gene expression levels are controlled
not at the transcriptional level, but rather by a mechanism
whichlikelymodulatesthestabilityofthematureRNAs[62].
Thus it is speculated that editing may play a central role
in controlling diﬀerent mitochondrial functions during the
development cycle of the trypanosomes.
3.4. The Nuclear Genome. The nuclear chromosomes of
T. brucei can be grouped into three classes according to
their sizes: 11 pairs of megabase chromosomes (1 to 6Mb)
that contain the house keeping genes and represent about
80% of the nuclear DNA content, a few intermediate-
sized chromosomes (200 to 900kb) and an undetermined
number of minichromosomes (in the range of 100 that
are 50 to 150kb) which comprise about 10% of the
nuclear DNA [63, 64]. The sequence of the 11 megabase-
sized chromosomes of Trypanosoma brucei contains 9068
predicted genes, including approximately 900 pseudogenes
and approximately 1700 T. brucei-speciﬁc genes. A large
subtelomeric arrays contain an archive of 806 VSG genes
used by the parasite to evade the mammalian immune
system.MostVSGgenesarepseudogenes,whichmaybeused
togenerateexpressedmosaicgenesbyectopicrecombination
[65].
3.5.Glycosomes. Thebloodstreamformoftrypanosomeshas
adapted its life in an abundance of glucose and relies entirely
on glycolysis and substrate level phosphorylation for their
energy production [66, 67]. The ﬁrst seven to nine enzymes
of the glycolytic pathway are present in the glycosomes,
the peroxisome-related small globular organelles [68], found
in all kinetoplastida. Expression of either phosphoglycerate
kinase or triosephosphate isomerase in the cytosol inhibits
parasite growth, suggesting that correct localization of the
glycolytic enzymes is important [69, 70]. Various results,
including the metabolic modeling, suggest that in blood-
stream T. brucei the glycosome plays a vital role in the
regulation of glycolysis [71–73]. The glycosomal membrane
of T. brucei is impermeable to several metabolites [72],
implying the presence of speciﬁc glycosomal metabolite
receptors. Indeed, with the proteomic data it has been
shown that there are certain receptors/carrier proteins in
the glycosomal membrane [74]. Because the glycosomes of
the bloodstream T. brucei together make up-to about 4%
of the total cellular volume, and the enzymes are present
at relatively high concentrations within the organelle, it
was postulated that their conﬁnement to a small volume
overcomes a diﬀusion limitation of the metabolites between
the glycolytic enzymes [66]. This led to the more general
notion that glycosomes would enable the trypanosomatids
to maintain their high glycolytic ﬂux. However, several argu-
mentshavebeenputforwardthatrendersuchanexplanation
unlikely [71]. Even though the glycosomal protein content
is dominated by the glycolytic enzymes, representing up to
90%, the glycosomes are not only involved in the glycolysis
but are predicted to carry out also the gluconeogenesis,
reactions of the hexose-monophosphate pathway, purine sal-
vage and pyrimidine biosynthesis, β-oxidation of fatty acids,
fatty acid elongation, and the biosynthesis of ether lipid
[75].
4. Unique Featuresof Trypanosomes
4.1.AntigenicVariationandImmuneEvasion. Trypanosomes
growing in the bloodstream of mammalian host need mech-
anisms to circumvent the host immune response. Antigenic
variationisoneofthemostspectacularadaptivemechanisms
exhibited by the African trypanosomes. The bloodstream
form of trypanosomes is entirely covered with a monolayer
made of 107 copies of the VSG, which is a major antigen
of the parasite whose antigenicity is in continuous changes.
During the ascending phase of the parasitemia, the majority
ofparasitesareofthesameantigenictype(calledhomotype).
The host immune system recognizes this homotype and
makes antibodies against it. As the parasites of the major
variable antigenic type (VAT) are eliminated the parasitemia
goes in descending phase but at the same time, the parasites
expressing the heterotype or the minor VATs are multiplying
and one of them overgrows others. As a result this one
becomes the new homotype, leading to a new wave of
parasitemia and resulting in a long-lasting chronic infection.
So expression of the VSG is central in the antigenic variation
process and eventually for exhausting the host immune
system in the beneﬁt of the parasite. For the immune
evasion, trypanosomes have also developed another method;
macromolecular traﬃcking mechanism [76] whereby the
VSG-complexed with antibody are sorted and endocytosed
[77]. This mechanism most probably protects the parasites
from the complement-mediated killing and as such the
trypanosomes escape from the host immune system. For
the purpose of escaping from the host immune system,
trypanosomes have more mechanisms such as capping of the
surface bound immune factors, restriction of the invariant
receptors in the ﬂagellar pocket, rendering them inaccessible
to the host immune eﬀectors [58].
4.1.1. VSG Expression. The trypanosome genome contains
hundreds of VSG genes (VSG) of which very few (7%)
are fully functional (encoding all recognizable features of
known functional VSG), whereas the majority (66%) are6 Journal of Biomedicine and Biotechnology
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full-length pseudogenes (with frame shifts and/or in-frame
stop codons) [65]. Most of these VSGs are clustered in the
subtelomeric arrays. Transcription of the VSG occurs in one
of the telomeres of the large chromosomes, which contain
the VSG expression sites (VSG ESs) [78]. These expression
sites are polycistronic transcription units having expression
site associated genes (ESAGs) upstream of the VSG. These
polycistronic mRNAs are matured by polyadenylation and
addition of a spliced leader sequence by a process called
transsplicing. Among the diﬀerent expression sites only one
is active at a given time. Thus only one of the VSG molecules
is present within the trypanosome surface coat, resulting
in the homogeneous display of an identical surface coat.
Transcription starts simultaneously in all VSG ESs, but only
in the “active” one there is complete transcription and all
the others are aborted [79, 80]. In the rapidly dividing long
slender form of trypanosomes, the active expression site was
found to be present in a specialized region called expression
site body (ESB) [81] and no similar structure was detected
for the silent expression sites.
4.1.2. Mechanism of Antigenic Variation. There are several
studies trying to unravel the diﬀerent systems involved in the
antigenic variation (reviewed by Pays et al. [80, 82, 83]. A
ﬁrst mechanism for the parasite to perform a VSG switch
is to change the expression site. By switching oﬀ the active
expression site [84] and activating a silent expression site,
a VSG switch takes place. However, as the VSG genes are
transcribed as polycistronic units, at the same time an ESAG
switch will occur. This type of VSG switching is called in
situ activation. This process could be one of the mechanisms
which makes it possible for the trypanosomes to survive in
variousconditionsandassuchextendingthehostrange[85].
A second system of the antigenic variation occurs possibly
via the VSG gene rearrangements including a reciprocal
recombination [86] and a gene conversion [87]. In this
system, the active site is not changed (and the ESAGs remain
the same) and only the VSG gene undergoes a modiﬁcation.
During the reciprocal recombination, the whole transcribed
VSG gene in one telomere is replaced by another VSG
gene present on a silent telomere [88]. This system occursJournal of Biomedicine and Biotechnology 7
by crossing over in the 70bp repeat region ﬂanking every
VSG gene on the promoter site of the gene. For the gene
conversion, an actively transcribed VSG gene or at least a
part encoding for the surface epitopes is replaced by a copy
of another VSG gene or a pseudogene, present on a silent
telomere or another location in the genome. This event
occurs more frequently than the reciprocal recombination
[86].
4.2. Resistance to Normal Human Serum. Humans and
some other primates [89, 90] are resistant to most of the
trypanosomes because of the presence of a trypanolytic
factor in their serum. The trypanolytic factor of the human
serum is discussed below. Two subspecies of T. brucei, T. b.
gambiense and T. b. rhodesiense, are resistant to the human
serum trypanolytic factor and thus are able to infect human
causing HAT or “sleeping sickness”.
The resistance to human serum, at least in case of T.
b. rhodesiense, is linked to an antigenic variation. It had
been shown that a gene called serum resistance-associated
(SRA) gene is only expressed in the resistant clone of T.
b. rhodesiense and not in the sensitive clone of the same
parasite [91–93] .T h eS R Aw a sn e c e s s a r ya n de n o u g hf o rt h e
resistance against normal human serum (NHS) [94]. It was
found that the SRA is associated, as an ESAG, to a speciﬁc
VSG ES, termed R-ES, which is selected in the human serum
by antigenic variation [94]. The expression of SRA by T. b.
rhodesiense is not a permanent phenomenon as it looses the
resistance to NHS in the absence of the trypanolytic factor of
the human serum, for example, after several passage in mice
[95] or the T. b rhodesiense which are found in nonprimate
animals [96]. The SRA contains all the characteristics of a
VSG except that the region coding for the surface-exposed
epitope is missing because of an in-frame deletion [97–100].
So SRA is a kind of truncated VSG. As in the VSGs, the SRA
contains the N-terminal α-helices [100], which in case of
VSG are involved in a coil-coil interaction with the adjacent
VSG to make the dimer [101], whereas this helix of the SRA
is responsible for neutralizing the human serum trypanolytic
factor by coil-coil interaction [102].
4.2.1. Trypanolytic Factor of the Normal Human Serum
(NHS). It has been known already for a century, reported
by Laveran and Mesnil between 1902 and 1912, (cited in
[98,103],thattheserafromhumansandotherprimatessuch
as baboon and mangabey can kill trypanosomes, although
there were diﬀerences in the killing activities within these
sera. Recently it has been shown that gorilla serum also
has trypanolytic activity but the serum from chimpanzees,
whichareevolutionarilymostclosetothehuman[104],does
not have trypanolytic capacity [89]. Further characterization
of trypanolytic factor (TLF) in the human serum showed
that the factor is associated with high-density lipoprotein
(HDL) [105, 106], and endocytosis of these HDL particles
by the trypanosome is necessary for the lysis [107, 108].
The trypanosomal receptor for the HDL is yet to be
deﬁned, but it is most likely to be a lipoprotein scavenger
receptor [109]. Two TLF complexes have been shown to
be present in the human serum; (i) TLF1, a 500kDa high-
density lipoprotein complex composed of apolipoprotein
A-I (apoA-I), haptoglobin-related protein (Hpr), apolipro-
tein L-I (APOL1), human cathelicidin antimicrobial pep-
tide (hCAP18), GPI-speciﬁc phospholipase D (GPI-PLD),
apolipoprotein A-II, and paraoxanase [106, 110], and (ii)
TLF2, a 1000kDa lipid poor immunocomplex composed of
apoA-I, Hpr, APOL1, hCAP18, GPI-PLD, and IgM [111–
113]. Among these components, Hpr has been thought for
a long time to be the active trypanolytic component of
TLF, because (i) it was considered to be the component
recognized by parasite surface [114], (ii) anti-haptoglobin
antibodies, which cross-react to the HPR, could inhibit the
TLF mediated trypanolysis [110, 115], and (iii) it is not
expressedinchimpanzeesserumwhichlacksthetrypanolytic
capacity[90]. But now there are more and more conﬁrmative
evidences showing that APOL1 is the trypanolytic factor of
normal human serum [89, 98, 102, 103, 116]. There are still
ongoing discussions on which component of TLF is the most
important for the trypanolytic activity. Some have suggested
that there is a synergistic eﬀect of Hpr and APOL1 for
which HDL provides the platform [117]. Others have shown
three human apolipoproteins (Hpr, APOA1, and APOL1)
acting cooperatively for maximal killing capacity; however;
the truncated APOL1 did not function in transgenic animal
[118]. Furthermore, recently it has been shown that baboon
contains orthologs of APOL1 and Hpr and when these
two genes were expressed together with APOA-1; there was
full protection against both animal and human infective
T. b. rhodesiense infection [119]. In addition, TLF can also
ameliorate infection by the intracellular parasite Leishmania
[120, 121].
In humans, the APOL family has six members (APOL1
to APOL6) which all are clustered in the chromosome 22
[122–124]. APOL1 is only found in the sera from humans
and gorilla which have the trypanolytic capacity but not in
the chimpanzee serum which lacks the trypanolytic potential
[89]. There are growing evidences that support APOL1 to
be the active trypanolytic component of TLF: (i) APOL1
depleted NHS lost the trypanolytic capacity, (ii) this lost
function could be rescued by adding a physiological con-
centration of both natural and importantly the recombinant
APOL1, (iii) physiological concentrations of APOL1 lysed
trypanosomes in fetal calf serum (FCS), showing that the
addition of only APOL1 is enough to have trypanolytic
activity in FCS, and (iv) APOL1 was lytic only to the NHS
sensitive strain and not to the NHS resistant strain, showing
that killing by puriﬁed APOL1 is not due to the toxicity
acquired in the puriﬁcation process [98, 102, 103]. APOL1
containsasignalsequence(aminoacid1-27)andthesecreted
protein could be divided in three domains in relation
with trypanolysis: a pore-forming domain, a membrane-
addressing domain, and an SRA-interacting domain [116].
The pore-forming domain, which spans from Met60 to
Trp235, has structural and functional similarities with the
pore-forming domain of bacterial colicins. Next to the pore-
forming domain there is the membrane-addressing domain,
Ala238 to Pro304, which is predicted to bind to HDL
particles only in neutral pH such as blood. At the C-terminal8 Journal of Biomedicine and Biotechnology
of APOL1, there is anα-helix which interacts with the SRA
of T. b. rhodesiense and this interaction leads to a loss of
trypanolytic capability of the APOL1. The pore-forming and
the membrane addressing domains are necessary for the
trypanolytic capacity whereas the SRA-interacting domain
is dispensable. In fact, removal of this C-terminal domain,
by which the SRA can no longer interact, makes the APOL1
even lytic to NHS-resistant T. b. rhodesiense [98]. Therefore,
this truncated molecule can be envisaged as a possible
therapeutic molecule of human origin.
4.2.2. Mechanism of Trypanolysis by APOL1. The mech-
anism of trypanolysis by APOL1 has been proposed by
Pays et al. [93] and Baral et al. [103]. The APOL1 which is
associated with HDL particles are internalized by the blood-
stream form of trypanosomes via HDL-receptor mediated
endocytosis in the ﬂagellar pocket. The endocytic pathway
leads the APOL1-loaded HDL to the endosomes and then
to the lysosomes. The acidic pH of the lysosome induces
a conformational change in the pH sensitive membrane-
addressing domain of the APOL1. This conformational
change would cause a dissociation of the APOL1 from the
HDL and leads to association with the lysosomal membrane.
At this stage the pore-forming domain would be able to form
ionic-pore in the lysosomal membrane causing an inﬂux of
chloride ions (Cl−) from the cytoplasma to the lysosomal
lumen. There would be a compensatory inﬂux of Cl− to the
cytoplasma via ion channels in the plasma membrane. In the
plasma membrane the anionic inﬂux can be accompanied
by some other cationic inﬂux as well [112]a sH p ri s
suggested to permeabilize both anionic and zwitterionic
membranes [125]. The ionic inﬂux leads to the movement
of water to the lysosome causing an osmotic swelling of
this organelle. This uncontrolled swelling of the lysosome
can cause an increased intracellular pressure which might
cause the plasma membrane damage and ultimately kill the
parasite. The SRA protein expressed by T. b. rhodesiense
interacts with the C-terminal domain of APOL1 in the
endosomes and/or lysosomes which prevents the APOL1
being able to form the pore, and as such makes the parasite
resistant to the APOL1/NHS.
5. The Surface Proteinsof the Trypanosomes
Trypanosomes are covered by their stage-speciﬁc surface
proteins. In the bloodstream form they are covered by the
VSG and in the procyclic insect form they are covered by
another protein called procyclins. The procyclins are GPI-
anchored glycoproteins with either ﬁve or six pentapeptide
repeats (GPEET procyclin) or up to 30 glutamic acid-prolin
dipeptide repeats (EP procyclin) [126, 127].
5.1. Variant-Speciﬁc Surface Glycoprotein (VSG). The VSG is
the most abundant surface protein in the bloodstream form
of the trypanosomes. It forms a dense surface coat of 12-
15nm over the entire surface of the trypanosome [128]a n d
accounts for about 10% of the total protein content of the
bloodstream form of the parasite and more than 95% of
the externally disposed cell surface protein [128]. Nearly the
entire cell surface of the parasite and the ﬂagellum is covered
by the VSG. The bloodstream form of the trypanosome is
coated with a continuous layer of approximately ﬁve million
densely packed identical homodimers of VSGs [128, 129]
thatprovidetheparasiteadefensebarrieragainstbothinnate
and speciﬁc immune eﬀectors of the host [130].
5.1.1. Structure of VSG. VSGs are antigenically distinct due
to extensive diﬀerences in primary sequence. Despite the
diﬀerences in the primary structure, it is believed that
the VSGs have a conserved tertiary structure which could
explain how arrangement of the VSGs with diﬀerent primary
sequences can perform the same apparent function of
producing a monolayer barrier that prevents binding of the
host complement components or other lytic components
that are present in the serum of the host [131]. The main
feature of the VSG tertiary structure is the formation of two
longalphahelicespermonomerthatareperpendiculartothe
cell surface and deﬁne the elongated shape of the VSG [132].
Due to the elongated shape and densely packed composition,
only a very limited number of amino acids are accessible to
the extra cellular environment which might be hostile. The
mature VSG polypeptide has 400–500 amino acid residues
(most having between 420 and 460) consisting of two or
three domains, namely, N- and C-terminal domains [133].
The majority of the sequence forms a single N-terminal
domain of 350–400 residues and the remainder one or two
smaller C-terminal domains of 40–80 residues each [133–
135]. Otherthancysteine residues, there is little conservation
of primary sequence within the N-terminal domain whereas
the C-terminal domain has a greater degree of primary
sequence identity [135]. The C-terminal domain is attached
to the membrane of the parasite by a glycosyl-phosphatidyl-
inositol (GPI) anchor [136]. Both attachment of the GPI
anchor and the N-glycosylation of the VSG occur in the
endoplasmic reticulum during the transportation of the
protein towards the surface. The attachment of the GPI is
essential for further transport of the VSG [137]. An N-
terminal part of the VSG, containing about two thirds of the
mature polypeptide can be cleaved oﬀ by exogenous protease
cleavage.
The three dimensional structure of this N-terminal
domain of T. brucei VSG has been resolved at high resolution
[138].Thedimerwasfoundtobe ±100 ˚ Alongandhavingan
asymmetrical cross section being 60 ˚ A × 40 ˚ A at the bottom,
30 ˚ A × 20 ˚ A in the middle and 45 ˚ A × 45 ˚ A near the top in
which the top of the molecule is normally exposed to the
external environment. This top part represents the hyper-
variable part of the VSG molecule and is stabilized by two-
conserved disulﬁde bridges [139] .T h eN - t e r m i n a ld o m a i n
of VSG ends with an α-helix which is followed by a single C-
terminal domain which is attached to the parasite membrane
with the GPI anchor.
5.1.2. The GPI Anchor. Each VSG and related molecules like
the ESAG6 is attached to the bloodstream form T. brucei
cell surface by a GPI anchor [136, 140, 141]. GPI anchorsJournal of Biomedicine and Biotechnology 9
inﬂuence the traﬃcking of the VSG in the early and late
secretory pathway [142], and play an important role in the
expression of the VSG on the surface of the parasite [143].
5.1.3. Structure of the GPI Anchor. The ﬁrst GPI-anchor
structure determination, as well as the ﬁrst description of
the mechanism of GPI biosynthesis were both established
using trypanosome VSG [136, 144–146]. This GPI-anchor
is preassembled as a GPI precursor with the following
structure: NH2CH2CH2-PO4H-6Manα1-2Manα1-6Manα1-
4GlcNα1-6myoinositol-1-PO4H-3(sn-1,2-di-Myristoylglyc-
erol, [147]. This core is attached to the mature C-terminal
amino acid in exchange for a hydrophobic C-terminal
GPI-addition signal peptide [140]. The VSG-linked GPI
anchors are subsequently substituted with unique galactose
side-chain residues, not present in other mammalian GPI
anchored proteins [136]. Another unique feature of the
trypanosome GPI anchor is that it contains exclusively
myristate (a 14-carbon, saturated fatty acid) as lipid moiety
[148]. As analogues of myristate are selectively toxic for the
parasites, the GPI biosynthesis pathway can be a potential
candidate for treatment of trypanosomiasis [149, 150].
Trypanosomes contain an endogenous phospholipase-C
(PLC) known as the GPI-PLC that is capable of hydrolyz-
ing the GPI-anchor of the membrane-bound form VSG
(mfVSG) [151]. This PLC is located primarily in the
membrane of the ﬂagellar pocket and is possibly part of the
VSG-membranerecyclingsystem[152].Itishighlyexpressed
in the bloodstream form parasites (30000 copies per cell)
and severely down-regulated in the procyclic form [153,
154]. The GPI-PLC expressed by one parasite only targets
its own plasma membrane and as such is unable to release
the VSG of another parasite [155]. As a consequence the
death of one parasite would not harm others. The GPI-
PLC under stress condition cleaves oﬀ the VSG leaving
the dimyristoyl glycerol (DMG) in the membrane and the
glycosil inositol phosphate (GIP) fraction on the released
soluble VSG (sVSG) [156–158]. This conversion can be
detected immunologically as it results in the exposure of
the cryptic cross-reacting determinant (CRD) [158–160] . A
low rate of the sVSG release from trypanosomes has been
observedintheculturesofthebloodstreamformsandclearly
demonstrated not to result from the lysis of a subset of
the population [161]. In addition, release of the sVSG can
be induced under stress conditions that do not lyse the
parasites [162]. Both of these observations suggest that GPI-
PLC acts on the mfVSG in living trypanosomes and not
just on cell lysis. The VSG and the GPI-PLC show the same
developmentally regulated expression, being found in the
blood-stream form and not in the procyclic form [154]. The
ability of the GPI-PLC to catalyze the shedding of the VSG
coat in vitro, and the contemporal expression of the two
proteins,hasledtothemodelsthatsuggestanimportantrole
for the enzyme in the developmental changes that involve
alterations in the expression of cell surface proteins [163].
However, by analyzing a GPI-PLC null mutant trypanosome
it was shown that the GPI-PLC is not essential and is
not necessary for antigenic variation, though it inﬂuences
parasitemia in mice [164]. Moreover, beside the GPI-PLC
activity, there is a zinc metalloproteases (MSP-B) activity
which also causes shedding of pre-existed VSG and which
even could be playing a quantitatively major role than the
GPI-PLC [25, 26].
5.2. Other Surface Proteins. Even though trypanosomes are
covered mainly by their stage speciﬁc major surface proteins,
some other surface proteins are also present which might be
located either beneath the surface coat of the VSG/procyclin
or within the ﬂagellar pocket. Some of these are invariant
surface proteins, others are receptors and transporters [165].
5.2.1. Invariant Surface Glycoproteins (ISGs). Due to the low
abundance of ISGs, it is not very easy to identify minor
surface proteins in the trypanosome. However, by use of
diﬀerent techniques some invariant surface glycoproteins
(ISGs) have been identiﬁed, such as ISG 60, ISG 65 and
ISG 75 [130, 166], ISG 64, and ISG 70 [167]. The ISGs
6 5a n d7 5b o t ha r ep r e d i c t e dt ob ec o m p o s e do fl a r g e
extracellular domains, a single transmembrane domain, a
small C-terminal intracellular domain and are not accessible
for antibodies on live parasites. Using ﬁxed parasites, it was
shown that both of them were distributed over the entire
cell surface. The ISG65 and not the ISG75 has been shown
to elicit an antibody response in the chronically infected
mice [130]. Another invariant protein with a single copy
gene, ISG 100, has been described. It is present in the
ﬂagellar pocket and is associated with the endo/exocytosis
compartments. This suggests that it might play a role in the
pathway for the endocytosis or it may have a structural role
in the compartments involved in intracellular traﬃcking of
T. brucei [168].
5.2.2. Surface Receptors. For the uptake of diﬀerent
molecules from the host, trypanosomes use diﬀerent
receptors. Not many receptors have been characterized in
the trypanosomes, so far. One of the best characterized
receptors in the trypanosomes is the transferrin receptor.
African trypanosomes grow in the bloodstream of diﬀerent
mammals where they take up their nutrients required
for growth. Iron is one of the crucial molecules for the
trypanosome survival [169]. Iron requirement of the
trypanosomes is fulﬁlled by a receptor-mediated uptake of
the host transferrin (Tf) [170–172]. Unlike the mammalian
transferrin receptor (Tf-R) which is a homo-dimer
transmembrane protein distributed over the surface of the
cell and binding two Tf molecules [173], the trypanosomal
Tf-R, located in the ﬂagellar pocket membrane, is a
hetero-dimer constructed from two very similar VSG-like
N-terminal domains [174] and binds only one molecule
of Tf [170]. The trypanosomal Tf-R diﬀers in primary
structure, subunit organization and mode of anchorage
from its human counterpart [175]. Another important
receptor might be the lipoprotein scavenger receptor which
is involved in uptake of the LDL, HDL as well as the human
trypanolytic factor (TLF) [109]. In addition to the scavenger
receptor another LDL receptor has been described to be
present in the ﬂagellar pocket [176, 177]. There are reports10 Journal of Biomedicine and Biotechnology
that small molecules are taken up by the trypanosomes via
transporters like the glucose transporters [178]t ot r a n s p o r t
glucose, the nucleoside transporters with diverse substrate
speciﬁcities and distinct patterns of expression during the
trypanosome life cycle [179].
6. ImmuneResponses duringInfection
with AfricanTrypanosomes
The immune response of vertebrates consists of two arms:
the innate immune response which has a low speciﬁcity and
the adaptive immune response which is antigen speciﬁc. The
immunology of infections by the African trypanosomes is a
complex process and has been recently reviewed [180, 181].
Being an extracellular parasite, the African trypanosome
encounters both the innate as well as the adaptive immune
response from the host.
6.1. Innate Immune Response against African Trypanosomes.
Once in the bloodstream of the mammalian host, the
trypanosomes encounter the innate host immune system as
the ﬁrst barrier. As already mentioned, human and some
other primates have trypanolytic factors in their serum that
aid the primary defense mechanism.
In a cellular innate immune response, diﬀerent host cells
are activated by diﬀerent trypanosomal factors, initiating an
acute inﬂammatory response [182, 183]( Figure 4). Among
many molecules, the trypanosomal DNA that might be
released from the dead trypanosomes has been shown to
activate macrophages in a process called classical activa-
tion, to secrete proinﬂammatory molecules like TNF, IL-
12 and NO [184, 185]. In this regard, the involvement of
toll like receptors (TLR) and in particular the TLR9, in
parasitemia control [186], would suggest that the DNA from
trypanosomes plays a role in disease progression. The GPI
anchor of the VSG also interacts with the macrophages (via a
putative receptor which is still elusive) and induces secretion
of pro-inﬂammatory cytokines [187–189]. So, the ﬁrst
response of the host immune system consists of classically
activated macrophages (caMφ) secreting pro-inﬂammatory
molecules such as TNF, IL-1, IL-6, NO (219–221). The
caMφs can phagocytose antibody-opsonised parasites [190]
as well as secrete trypanotoxic molecules such as TNF and
NO [191–194] that are involved in the control of the ﬁrst
peak of parasitemia.
6.2. Adaptive Immune Response. The initial inﬂammatory
response is beneﬁcial to the host at the early stage of the
infection, but a sustained inﬂammation can cause pathology.
Hence, it is essential for the host to reduce the inﬂammation
which is obtained by down regulating the caMφ and
their pro- inﬂammatory cytokines. Production of type II
cytokines such as IL-4, IL-10 and IL-13 which can modulate
the macrophages to become more anti-inﬂammatory type
alternatively activated macrophages (aaMφ)a r ei n v o l v e d
in a longer survival of the host (Figure 4). So a type I
inﬂammatory response at the beginning of the infection
and a shift to the type II immune response in the late
stage of the infection are correlated with the capacity of the
host to control the parasite and the pathology respectively.
In a murine model, it has been shown that the VSG-
speciﬁc cytokine responses associated with the resistance
to the murine African trypanosomosis are infection-stage
dependent, with the type-I cytokine responses being critical
during the early stage of infection while the type-II cytokine
responses to be more important during the late and chronic
phases of the disease [195]. Several studies suggest that
the cytokine responses inﬂuence the outcome of African
trypanosomiasis [196–199]. However, the precise role of the
individual cytokines is still equivocal and may be dependent
on the parasite strain, the mouse model or both. In this
context the role of IFN-γ [196] for resistance against T.
b. rhodesiense and the role of IFN-γ and NO together
with the antibody response have been shown to be crucial
in the control of T. congolense infection [200]. However,
in the T. evansi m o d e le v e nt h o u g hT N F ,I F Na n dN O
levels are elevated in the early stage of infection, none of
these molecules seem to be important for the parasitemia
control as well as the survival of the host [201]. In another
trypanosome model, T. borelli, a blood parasite of carp,
NO hinders antibody clearance from the surface of the
parasite and increases susceptibility to the complement lysis
[202]. Moreover, Magez et al. [203, 204] demonstrated that
TNF plays a key role in both parasitemia controls as well
in the development of pathology in T. brucei infections.
Concerning the role of type II cytokines, some have shown
that CD4+ T cell regulated IL-4 production was crucial for
controlling T. b. gambiense infections in mice [198]a n da
role for IL-4 in resistance to bovine trypanosomiasis was
also proposed [199] while others [196] reported that IL-4
knockout mice do not show any alteration in the parasite
control. Namangala et al. [205] showed that during the
chronic stage of infection a Th2 cytokines production as well
as a IgG1 antibody response to the trypanosome antigens are
linked to the longer survival of the host in T. brucei infection
model. Moreover, the levels of IL-10 and IL-6 in the brain
have been shown to be associated with the protection from
neuroinﬂammatory pathology of HAT [206, 207].
6.2.1. Humoral Responses. During the trypanosome infec-
tion a dominant humoral response of the host is expected,
since the location of the parasite is extra-cellular. Both
the murine and bovine trypanosomiasis is characterized
by a polyclonal B cell activation as evidenced by an
increased number of B cells and a signiﬁcant elevation
in plasma Igs [209–211]. Because of the polyclonal B
cell activation, a signiﬁcant component of the resultant
antibody is either polyspeciﬁc or auto reactive [212–214].
Although the VSG molecules are highly immunogenic for
all mouse strains upon immunization, dramatic diﬀerences
in the ability of animals to mount the VSG-speciﬁc B cell
response occur after infection [215]. It is shown in dif-
ferent independent studies that speciﬁc antibodies directed
against the trypanosome VSG mediate the destruction and
clearance of parasites in successive parasitemic waves and
hence contribute to antibody-mediated trypanotoleranceJournal of Biomedicine and Biotechnology 11
[197, 213, 216, 217]. Animals immunized with the irradi-
ated trypanosomes or the VSG are successfully protected
against a challenge with the homologous parasites [218,
219]. The antibodies directed against the speciﬁc surface-
exposed epitopes of the VSG coat opsonize the parasites
and the immune complexes are eﬃciently phagocytosed and
destroyed, mainly in the liver, by the macrophages (Kupﬀer
cells) [190, 220, 221].
During African trypanosomiasis, the VSG-speciﬁc B
cell responses can occur in a T-cell independent manner
[222]. However, the T-cells improve the B-cell responses,
mainly by secreting cytokines mediating antibody class
switching.InthiscontextanincreasedIL-4mRNAlevelanda
concomitant increase in the IgG1 antibodies against the VSG
was observed in the trypanotolerant N’dama cattle infected
with T. congolense but not in the trypanosusceptible Boran
cattle [199]. In animal trypanosomiasis, trypanotolerance is
a combination of the humoral response needed for parasite
controlaswellastheabilitytocontroltheimmunopathology
(described below) which is the cause for loss of productivity.
Schoﬁeld et al. [223] described a rapid major histocompat-
ibility complex (MHC)-unrestricted antibody response to
the diverse pathogens including the trypanosomes. These
authors demonstrated the CD1d-restricted IgG formation
in response to Plasmodium and Trypanosoma GPI anchored
antigens mediated by IL-4 producing CD4+, NK1.1+ helper
T-cells (NKT cells) and proposed that this may represent a
generalmechanismforarapidresponsetotheGPI-anchored
surface antigens and the parasite control.
Although the trypanosome-speciﬁc antibodies are pro-
duced in the early stage of infection and may be protective as
they mediate parasite clearance [224–228], remove immune
complexes [229], and possibly neutralize the parasite prod-
ucts, yet a signiﬁcant proportion of the antibodies is either
polyspeciﬁc or auto-reactive [209, 213, 214, 230, 231]. More-
over, later in the infection, the B-cells become suppressed
or exhausted, resulting in a total absence of IgG responses
and a strongly reduced IgM response [232]. Using B-cell
(μMT) and IgM-deﬁcient mice, it has been shown that in
the murine experimental T. brucei trypanosomiasis, B-cells
werecrucialforperiodicpeakparasitemiaclearance,whereas
the IgM antibody played a limited role [233]. However, in
the T. evansi infection model, the IgM has been shown to
play an important role in the control of the disease [201]
suggesting the role of diﬀerent antibodies can vary with
diﬀerent trypanosome strains.
6.3. Immunosuppression. One of the striking features of the
trypanosome infections is the dramatic suppression of the
immune responses, which might result in a high susceptibil-
itytoopportunisticinfections.Thegeneralizedimmunesup-
pressionhasbeenreportedtoaﬀectalargevarietyofboththe
humoral (B cell) and the cellular (T-cell and macrophage)
immunefunctions[234],consequentlyleadingtooccurrence
of the trypanosome-induced immunopathology [235–237].
Although the existence of the immunosuppression has been
known for long time, the unresolved question was whether
the immunosuppression was mediated by the macrophages
or the T cells. There are suggestions that both cells might be
involved [238]
Suppressive macrophages elicited by the T. brucei infec-
tion play a central role in the immunosuppression observed
in this infection [239–241]. The immunosuppression is
characterized by an inhibition of the T cell proliferation due
to down regulation of both IL-2 production and expression
of IL-2 receptor [235, 240]. Prostaglandins and nitric
oxide (NO) impair mitogen-induced T-cell proliferation
in the spleen, peritoneal cavity, and lymph nodes of T.
brucei infected mice but only during the early stage of
infection [241–243]. At the early stage of the infection, the
involvement of TNF and IFN-γ in the inhibition of T-cell
proliferation seems to be involved in an up-regulation of
prostaglandins and NO synthesis [204, 244]. In addition,
TNF promotes the development of suppressive cells by
inducing IFN-γ production in the lymph nodes of T. brucei
infected mice [244]. Moreover, T. brucei infection also
impairs the MHC class II antigen presenting capacity of
the classically activated macrophages [245] resulting in a
reduced T-cell activation. But at the late stage of infection,
inhibition of T-cell proliferation in the lymph nodes occurs
through NO/prostaglandin independent pathway, whereby
IFN-γ released by CD8+ T-cell plays a crucial role [242,
246]. There are reports showing at the late stage of infec-
tion, macrophages displaying an anti-inﬂammatory cytokine
production, which might modulate in several aspect of
the immune system as the infection progresses [247, 248].
FactorslikeIL-10secretedbythemacrophagesoftheinfected
animals are shown to inhibit antigen presentation [249]
and contributing to the impairment of T-cell activation.
However, the mechanisms of suppression by the alternatively
activated macrophages elicited at later stage of the African
trypanosome infections are not fully understood. Regulatory
T cells (Tregs) have also been shown to limit the production
of IFN-γ by CD4+ and CD8+ T cells and also down regulate
the activation of macrophages [250, 251]. Furthermore,
these Tregs are suggested to suppress the NKT cell [238].
Presentation of glycolipids to the NKT cells in the context
of CD1d have been suggested in the trypanosome infection
[238] or a GPI treatment [252].
6.4. Immunopathology. As mentioned above, uncontrolled
type I immune reaction of the host leads to a pathological
condition. The major pathological complication associated
with the human trypanosomiasis is the neurological disorder
which is ﬁnally manifested as ‘sleeping sickness’. However
the pathological symptoms observed in experimental try-
panosomiasis are mainly loss of body weight, fever, reduced
locomotory activity, splenomegaly, and liver damages. One
of the common pathological features observed in human,
bovine as well as the experimental murine trypanosomiasis
is the loss of red blood cell count, that is, anemia. Here,
the degree of anemia might be considered as an indicator
of the disease severity [253]. At least in case of the bovine
trypanosomiasis, one aspect of the trypanotolerance is
the measurement of the ability to control the infection-
associated anemia and subsequently the loss of productivity12 Journal of Biomedicine and Biotechnology
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Figure 4: Trypanosome-host interaction (from [208]). Model for induction classical (caMφ) and alternative activation (caMφ)o f
macrophages during trypanosome infection; TLTF: trypanosome-derived lymphocyte-triggering factor.
of the host [254]. Anemia during trypanosomiasis might be
duetoeitherlossofRBC,forexample,thecytokine-activated
macrophages (M1 cells) are suggested to be responsible for
the enhanced phagocytosis of parasites as well as the RBCs
[255] or due to inability to mount a vigorous compensatory
erythropoietic response [255, 256].
During trypanosome infections, TNF is involved both
in parasitemia control and infection associated pathology
[204] such as anemia, neurological disorders, fever and
cachexia during both human and animal trypanosomiasis
[234, 257]. In view of this dual role, lots of works reveal
how trypanosomal components induce TNF. In this regard,
VSG was identiﬁed as major TNF inducing component in
trypanosome-soluble extract. Both sVSG and mfVSG were
shown to manifest similar TNF inducing capacities but by
a detailed analysis it was indicated that they are working
in a diﬀerent way. The GIP moiety of the VSG via the
GIP associated galactose side chain is responsible for direct
induction of TNF. Yet, the mfVSG, but not the sVSG,
stimulates macrophages toward IL-1 secretion and acquisi-
tion of the LPS-responsiveness and is, as such, involved in
indirect TNF production. Thus, the VSG has two distinctJournal of Biomedicine and Biotechnology 13
macrophage activating components [258]. TNF can signal
for cellular activities through 2 diﬀerent receptors; TNF-
R1 (CD120a) and TNF-R2 (CD120b). It is suggested, that
TNF-R2 signaling in trypanosomiasis mediates infection-
associated pathology, whereas TNF-R1 signaling has no
impact on infection [259].
It was also shown that serum TNF levels correlate with
the severity of neuropathological symptoms in the human
sleeping sickness [260]; however, some studies found no
correlation between the TNF serum level and pathology of
the HAT [261, 262]. In the same line of research, there are
reports that demonstrate the enhanced expression of TNF
mRNA in the brain of T. brucei-infected mice [263, 264]
and the correlation in trypanosome-infected cattle between
TNF production by monocytes and the severity of diseases-
associated anemia [265]. Hence, the accumulated knowledge
about trypanosome-elicited production of TNF indicates
that while this cytokine might be beneﬁcial during the early
stage of infection through its role in parasite clearance, the
overall pathology-inducing aspect overrules in a negative
way.Asoutlinedbefore,duetohighlysophisticatedantigenic
variation, an antiparasitic vaccination seems to be very
diﬃcult. However, the knowledge of the immunopathology
gives a basis for a design of an antidisease vaccination.
7.CurrentandAlternativeControlStrategies
for Trypanosomiasis
The control of trypanosomiasis can be approached from
three diﬀerent aspects: control the vector, vaccinate the host
as a preventive measure, or treat the infected host. All three
approaches have their own beneﬁts but at the same time
suﬀer from some diﬃculties.
There are diﬀerent vector-control methods currently
available; use of insecticide (through the sequential aerosol
spraying technique, insecticide-treated targets or insecticide
treated animals), use of traps, and the sterile insect technique
(reviewed [266]). Technical improvements to make these
methods cheaper, more eﬃcient and less time consuming are
still needed [267]. In an attempt to develop a cost eﬀective
control method for Glosina ﬁscipes, a perspect for developing
the odour baits based on the kairomones present in lizard
odour and pig odour have been suggested [268]. In all these
and other studies it has been agreed that more precise and
possibly new method of vector control are still in demand.
One of the problems associated with the use of chemical
insecticides as a vector control is the evolution of resistance
against that chemical. As an alternative approach, one may
think about an “evolution-proof” insecticide as has been
discussed for the malaria control [269].
The current treatment of HAT is based on four
main drugs, namely suramin, pentamidine, melarsoprol,
and eﬂornithine (diﬂuoromethylornithine or DFMO), with
nifurtimox undergoing evaluation [270, 271]. Most of these
drugsweredevelopedintheﬁrsthalfofthetwentiethcentury
and there has been no new registered drug since 1981.
The candidate drug called DB 289, a dimidine derivative
has ﬁnished clinical trial II [270–272]. Early-stage disease
is treated with an intravenous injection of suramin in
rhodesiense disease and with an intramuscular pentamidine
in gambiense disease. The arsenical melarsoprol is the only
eﬀective drug for the late-stage disease in both forms of
the HAT, as the drug crosses the blood brain barrier [272].
Nifurtimox taken orally for 1 to 2 months and DFMO with
an administration scheme spread over ﬁve weeks including
14 days of intravenous injection can be other alternatives.
However, the DFMO is not commonly available and is
considered too expensive for routine use. Moreover, the
DMFO is known to be active only against T. b. gambiense
[273].
Themajorproblemsoftherapyarethefrequentandoften
serious adverse events due to drug toxicity, relapses, and
the long duration of treatment. The worst adverse events
are encephalopathic syndromes, which occur in 5–10% of
patients, and result in the death in 10–50% of those in whom
the encephalopathy develops. Other severe adverse reactions
reported are polyneuropathies (up to 10%), exfoliative der-
matitis, fever, headache, diarrhea, maculopapular eruptions,
pruritus, and abdominal and chest pain [274, 275]. There are
reports for a shorter treatment regime of melarsoprol [276,
277] or a combination of melarsoprol with suramin [278].
Drug resistance in trypanosomes appears to be increasing
in the ﬁeld and is now hindering eﬀorts to control the
HAT. Failures of the melarsoprol treatment, the preferred
treatment during the encephalitic stage of T. b. rhodesiense
infections, have reached alarming levels. The unacceptable
toxicity of the currently available drugs for HAT underpins
the urgency of developing more eﬀective and safer drugs
[270].
Control of African bovine trypanosomiasis mainly relies
in endemic areas on chemotherapy and chemoprophy-
laxis using three trypanocidal compounds; isometamidium,
homidium and diminazine. Suramin and quinapyramine are
also in practice since long time in animal trypanosomiasis
treatment. All of these drugs have been in widespread use
for about 40 years and resistance has been reported in many
parts [279–282]. Resistance to the Berenil (a drug commonly
used for treatment of livestock trypanosomiasis [283]) has
also been reported in several foci [284].
The resistance to drugs for the African trypanosomes has
been shown to be associated with reduced drug uptake by
the parasites stressing the importance of drug transporter
(reviewed by [285]). Reduction of net drug uptake can be
caused by either a decreased drug import or an increased
drug export. Either mechanism implies mutations in the
transporters since most trypanocides do not freely diﬀuse
through the plasma membrane. In this context, the adenine
nucleoside transporter (P2-transporter) has been found to
be the transporter for arsenical as well as pentamidine [286,
287]. That provides an explanation for the frequent occur-
rence of cross-resistance between arsenicals and dimidines in
T. brucei spp. [288]. A trypanosome gene (TbAT1)p r o d u c t
exhibits P2-like transport activity but this is not the only
transporter for the trypanocidal drugs, indicating that drug
resistance involves the loss of more than one transporter
[289]. Besides loss of import to the parasite, increased export
of the drug also can be responsible for the drug resistance.14 Journal of Biomedicine and Biotechnology
In this aspect, over expression of one exporter, TbMRPA
(T. brucei multidrug-resistance associated protein) caused
10-fold resistance to the melarsoprol in vitro [290, 291]
but such over expression in patients with treatment failure
with melarsoprol has not been reported yet. Similarly, over
expression of a gene TeDR40 has been shown to correlate
with Berenil resistance observed in T. evansi [292]. Besides,
alterations in drug import and export, there can be other
alternativemechanismslikefailuretoundergoapoptosismay
also contribute to the drug resistance. Diﬀerent resistance
mechanisms are not mutually exclusive. On the contrary,
drug resistance is often multifactorial.
Due to the facts that (i) there are very few drugs available
for the treatment of trypanosomiasis, (ii) the drugs being
used cause severe toxic eﬀects, and (iii) there are increasing
ﬁeld cases of drug resistance and there is a clear demand for
alternativetreatmentschemes.Furthermore,duetoantigenic
variation and immunosuppression, the conventional vacci-
nations strategies are not able to give promising results. So,
also in this regard alternative approaches are necessary.
Even a century after its ﬁrst description, the trypanoso-
miasis is still one of the major parasitic disease for which
control is far from reality. Most antitrypanosome drugs are
taken up by the parasite via speciﬁc transporters (e.g., P2
transporter). As a result, mutation on the gene encoding that
transporter can lead to multiple drug resistance [286, 287].
Therefore when new drug strategies for trypanosomiasis are
designed, they should rely on novel molecular and biochem-
ical pathways. The human trypanolytic factor, APOL1, has
beenexploitedasanalternativeapproachforthetreatmentof
HAT. APOL1 lyses trypanosomes except the ones which are
causing HAT [102]. In case of T. rhodesiense the resistance to
the trypanolytic capacity of APOL-1 is due to the expression
of serum resistance-associated (SRA) protein [94]w h i c h
neutralizes APOL1 through the interaction with the C-
terminal of this lipoprotein. Deletion of the SRA interacting
domain of APOL1 results in the generation of a new
molecule, that is, Tr-APOL1 that is lytic to both NHS-
sensitive as well as resistant T. rhodesiense. Hence, Tr-APOL1
represents a possible drug against all T. rhodesiense parasites.
However, to avoid the possible competition with the native
APOL1 in the serum, speciﬁc trypanosomal targeting of Tr-
APOL1 is essential. One such approach where the Tr-APOL1
has been conjugated with a single domain camel VHH that
targets the oligomannose moiety of VSG has been reported
[293]. The results in that study showed that treatment with
this conjugated Tr-APOL1 cured mice infected with either
NHS-resistant T. rhodesiense or NHS-sensitive T. brucei.T h e
treatment also had beneﬁcial eﬀect when used in the chronic
stageofthetrypanosomiasis,althoughinthiscaseacomplete
elimination of the parasite was not obtained [103]. The
results thus may suggest that, Tr-APOL1 could be developed
as an alternative drug for treatment of the early stage
HAT. Due to the fact that APOL1 is a human self-antigen,
and since VHH is highly homologous to human VH, the
authors of this paper suggest very minimal, if any, immune
response against the conjugated protein, when administered
to HAT patients. Furthermore, it has been shown that the
full length baboon APOL1 (which does not interact with
SRA) is protective against both the animal-infective and
human-infective T. rhodesiense in an experimental mouse
model,and,assuch,ithasbeensuggestedtocreatetransgenic
livestock that would be resistant to animal and human-
infective trypanosomes, which is envisaged to result in the
reduction of the livestock trypanosomiasis and zoonotic
transmission of human infective trypanosomes [119].
Beside treatment, eﬀective vaccination strategy is a
second approach for the control of any infectious diseases. In
the case of trypanosomiasis, all conventional anti-parasitic
vaccination eﬀorts undertaken so far, that used dominant
surface protein, have failed due to the antigenic variation
of the trypanosomes surface coat. Therefore, an alternative
strategy of the vaccination is demanding. As alternative
vaccination approaches, diﬀerent molecules such as try-
panosomal cystein protease (congopain) [294], trypanoso-
mal tubulin [295, 296] or trypanosomal GPI have been
attempted. The GPI-anchor of the VSG as one of the major
parasitic components causing the inﬂammatory response
associatedtotheinfectionhasbeenidentiﬁed[258].Inoneof
the studies, this information has been used to evaluate GPI-
based vaccination as an alternative strategy with antidisease
potential [252]. Using liposomes as slow delivery system, the
GPI administered prior to the infection had been shown
to result in a better control of the parasitemia and a
longer lifespan of the infected mice. The treated animals
were better protected from various pathological conditions
including anemia which is considered as one of the major
pathological parameters of the trypanosomiasis [254]. These
results are related to the fact that the treatment oriented
the classically activated inﬂammatory macrophages, to more
counter-inﬂammatory alternatively activated macrophages
[208], subsequently resulting in reduced TNF production
and reduced pathology. With the GPI-based treatment,
though there were positive eﬀects on the infection-induced
pathology as well as survival, but the animals were not
cleared from their parasites. Therefore, this strategy is
more an anti-disease approach rather than an anti-parasitic
strategy. While this solution would not be advisable for the
HAT where an antiparasitic treatment would be needed,
the persistence of a low level infection that would prevent
the severe disease might be preferred in the livestock ﬁeld
conditions, where the host has controlled geographical
movement and is under continuous threat of re-infection
by the infected tsetse ﬂies. The needs, possibilities and
requirements of further knowledge for the way to develop
an anti-disease control strategy for trypanosomiasis has been
recently highlighted [297].
8. Conclusion
Both the prophylactic as well as the therapeutic aspects of
trypanosomiasis need alternative approaches as currently
there is no vaccine and the drugs that are in use have several
short comings. Some such alternative approaches have been
initiated but still more detail and comprehensive strategies
should be envisaged. These approaches should be based on
the strong background of understanding the biology of theJournal of Biomedicine and Biotechnology 15
parasite as well as the host-pathogen interaction needs to be
further studied. One ﬁnal point of consideration for such
alternative approach would be its economical viability since
the disease aﬀects the poorest of the poor of the world.
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